Go to any scientific or biotech conference and chances are a good part of the program will be devoted to some aspect of proteomics and biomarker research. Over the past decade these two related research areas have drawn much attention as investigators seek to shed as much light as possible on the role of proteins in health and disease. One of main goals of this work is to get important research findings into the clinic as quickly as possible. Today’s podcast interviewee is one of the scientists at the forefront in carrying out such translational research.
This week's podcast interviewee is one of the scientists at the forefront in carrying out such translational research.The Director of the Fred Hutchinson Cancer Research Center's Early Detection Initiative, Dr. Amanda Paulovich tells us how proteomics can help move new cancer therapies more effectively out of the lab and into clinical applications. She explains what various proteomics approaches allow researchers and cancer clinicians to do now that was impossible ten or fifteen years ago. Dr. Paulovich provides details on which particular instruments and technologies used in proteomics research and clinical proteomic applications are essential to this effort of translating lab discoveries to the cancer clinic. She provides examples of proteomic alterations that may reflect the existence of cellular and molecular pathways linked to tumorigenesis and shows how these proteomic changes are measured in the serum/plasma proteome. She also discusses the best methods for describing and comparing proteomic data representation, and lists the advantages and disadvantages of the different techniques.
Listen now to this important discussion then return to the blog to give your thoughts on the following question:
What improvements in which specific tools and technologies do you think are necessary to help accelerate the transfer of research findings in proteomics and biomarkers into clinical applications?